Comparative Clinical Outcomes of Heart Failure Therapies: A Network Meta-Analysis

27 randomized controlled trials involving 65,929 patients compare finerenone, SGLT2 inhibitors, RAS inhibitors, and ARNI for heart failure with preserved or mildly reduced ejection fraction. The analysis, published on figshare by Zimin Fu in 2026, reports odds ratios for outcomes like cardiovascular death and worsening heart failure events. Results indicate finerenone was associated with a lower risk of CV death and worsening HF events compared to placebo.

Use Cases

• Compare the efficacy of different drug classes for HFpEF/HFmrEF based on reported odds ratios for clinical outcomes.
• Assess the safety profiles of finerenone versus SGLT2 inhibitors based on adverse event risk comparisons.
• Inform clinical trial design by synthesizing evidence from 27 RCTs on cardiovascular and renal endpoints.

Strengths

• Analysis includes data from 65,929 patients across 27 randomized controlled trials.
• Reports specific odds ratios with 95% confidence intervals for multiple clinical outcomes like CV death and worsening HF events.
• Uses a network meta-analysis methodology to enable indirect comparisons between drug classes.

Limitations

• The underlying dataset is not provided; the file contains only the analysis document.
• Row count and column-level data for the original trials are unknown.
• The description lacks details on individual patient data or trial-level covariates.

Provenance

Source

Zimin Fu via figshare.

Collection Method

Systematic review and network meta-analysis of randomized controlled trials sourced from PubMed, Embase, Cochrane Library, and Web of Science.

Time Range

Trials from database inception to 3 January 2026.

Freshness

Last updated 2026-05-15 05:41:06.